Charles Explorer logo
🇬🇧

The use of bevacizumab (Avastin) in treating recurrent cervical cancer

Publication at First Faculty of Medicine |
2017

Abstract

Recurrent, persistent or metastatic cervical cancer represents a major clinical problem. It is a tumour with a very unfavourableprognosis, being frequently diagnosed in younger women.

The treatment options in the case of such a tumour are limited, mainlyinvolving the administration of systemic palliative chemotherapy with a platinum derivative and/or non-platinum combinations inpretreated patients. More recently, it has been possible to utilize the beneficial effect of anti-angiogenic therapy in the palliativetreatment of this disease.

The present case report discusses clinical experience with the treatment of recurrent cervical cancer ina young patient by means of chemotherapy and anti-angiogenic therapy.